CAR Stock Recent News

Waymo said it plans to launch a robotaxi service next year in Dallas, the latest city to be added to the Alphabet-owned company's growing commercial footprint that already includes Los Angeles and San Francisco.

We had upgraded Canadian Apartment REIT to a strong buy due to robust Q4 results and management's strategic actions. The stock has outperformed our shorter term expectations. We review the recent results and update our thesis.

PARSIPPANY, N.J., July 22, 2025 (GLOBE NEWSWIRE) -- Avis Budget Group, Inc. (NASDAQ: CAR) announced today that it plans to report its second quarter 2025 results after the market close on Tuesday, July 29th, 2025, and to host a conference call for institutional investors to discuss these results on Wednesday, July 30th, 2025 at 8:30 a.m.

PARSIPPANY, N.J.--(BUSINESS WIRE)--Imagine this. You've just landed. Instead of wandering through a crowded parking garage or waiting for a shuttle, a welcome message pops up through your Avis app. By the time you reach the airport exit, your personal concierge is curbside with your premium vehicle. The cabin is cool, and your concierge helps you connect your CarPlay. No lines. No stress. Just the open road and a luxury experience that starts before you even put the car in drive. After you've c.

Approval is based on FELIX clinical trial of obecabtagene autoleucel (obe-cel) in adult patients with r/r B-ALL, demonstrating high and durable response rates and low toxicity EC approval follows positive CHMP opinion, MHRA conditional marketing authorization and FDA approval LONDON and GAITHERSBURG, Md., July 21, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, announces today that the European Commission (EC) has granted marketing authorization for AUCATZYL® (obecabtagene autoleucel or “obe-cel”) for the treatment of adult patients, 26+, with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (r/r B-ALL).

ANIX has a dual-platform approach. It has an FSHR‑targeted CAR‑T program for ovarian cancer and an α‑lactalbumin breast cancer vaccine. Their Phase 1 CAR‑T showed reasonable safety, as one patient remains alive after 24 months. Others have also exceeded the four‑month median survival. This means ANIX could start testing even higher doses, which might be even more effective.

APEMY, CAR and BIDU have been added to the Zacks Rank #5 (Strong Sell) List on July 14, 2025.

After Hertz's massive Ackman rally, this setup presented a good pair trade to long Avis and short Hertz. I bet this pair trade still has legs. Hertz is experiencing growing interest expenses that impact bottom-line performance, while Avis is actively reducing debt. Both companies are executing a fleet rotation strategy to enhance operational efficiency; however, Avis is well-positioned to benefit from this strategy as compared to Hertz.

NEW YORK , July 9, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Avis Budget Group, Inc. (NASDAQ: CAR)  breached their fiduciary duties to shareholders.  According to a federal securities lawsuit, Insiders at Avis caused the company to misrepresent or fail to disclose that (i) Avis Budget crafted and implemented a plan to significantly accelerate its fleet rotation in the fourth quarter of 2024; (ii) the foregoing acceleration shortened the useful life of the majority of the Company's vehicles in the Americas segment, thereby reducing their recoverable value; (iii) as a result, Avis Budget would be forced to recognize billions of dollars in impairment charges and incur substantial losses; (iv) all the foregoing was likely to, and did, have a significant negative impact on the Company's financial results; (v) accordingly, Avis Budget's financial and/or business prospects were overstated; and (vi) as

The meme-stock frenzy is seemingly making a comeback in 2025 as investors once again chase unprofitable companies for their latest bets.